Citius Oncology has entered a senior secured credit facility with Avenue Capital Group for up to $25 million, including an initial $10 million tranche, to support the commercialization of its FDA-approved cancer drug LYMPHIR. Concurrently, the company raised approximately $11.5 million through the exercise of warrants by a healthcare-focused investor. These financings provide Citius Oncology with enhanced financial flexibility to expand sales, market access, and manufacturing efforts for LYMPHIR, targeting relapsed or refractory cutaneous T-cell lymphoma. The funds will also support working capital and general corporate purposes as the company scales its commercial infrastructure.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...
Bath & Body Works introduced Fruit Fusion, a new body care franchise featuring fruit-inspired scents and hydrating formulas, available in the U.S. and Canada starting July 6, 2026. Actress Hilary Duff serves as the brand ambassador and creative partn...
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
